Citigroup Inc. upgraded shares of Merck & Company, Inc. (NYSE:MRK) to a buy rating in a report released on Monday morning.

A number of other equities analysts also recently commented on MRK. UBS AG decreased their price objective on shares of Merck & from $72.00 to $67.00 and set a buy rating for the company in a report on Monday. J P Morgan Chase & Co set a $70.00 price objective on shares of Merck & and gave the stock a buy rating in a report on Sunday. HSBC Holdings plc raised shares of Merck & from a reduce rating to a hold rating in a report on Wednesday, August 9th. Barclays PLC downgraded shares of Merck & from an overweight rating to an equal weight rating and decreased their price objective for the stock from $72.00 to $62.00 in a report on Monday. Finally, BidaskClub downgraded shares of Merck & from a hold rating to a sell rating in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $67.07.

Merck & (NYSE:MRK) last released its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 26.82%. The business had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same quarter last year, the company earned $1.07 earnings per share. The business’s quarterly revenue was down 2.0% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://theolympiareport.com/2017/11/02/merck-company-inc-mrk-raised-to-buy-at-citigroup-inc.html.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Merck & by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock valued at $12,442,709,000 after buying an additional 3,312,459 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Merck & by 71.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 6,281,855 shares of the company’s stock valued at $402,604,000 after buying an additional 2,618,435 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Merck & by 40.4% during the 2nd quarter. Principal Financial Group Inc. now owns 8,012,726 shares of the company’s stock valued at $513,535,000 after buying an additional 2,304,142 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of Merck & by 70.4% during the 1st quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock valued at $353,841,000 after buying an additional 2,300,200 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its holdings in shares of Merck & by 36.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,766,906 shares of the company’s stock valued at $497,774,000 after buying an additional 2,070,487 shares during the last quarter. 72.86% of the stock is currently owned by institutional investors.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.